FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced a significant advancement in its efforts to develop therapeutics for chronic diseases. The company has confirmed that its CYWC628 master cell bank can be utilized to manufacture CybroCell™, an investigational cell therapy aimed at treating degenerative disc disease $(DDD)$. This development allows the company to proceed with amending its Investigational New Drug $(IND.AU)$ clearance with the FDA for a planned Phase I clinical trial for DDD. Additionally, FibroBiologics has verified that the CYWC628 spheroids used in its wound healing program can be differentiated into chondrocytes, which are essential for cartilage formation, indicating progress in its cartilage repair program. The results of these advancements have not yet been presented publicly.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。